CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
146.35
1.27%
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.18
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Abbvie Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 144.51
Open* 144.93
1-Year Change* -11.52%
Day's Range* 144.93 - 146.91
52 wk Range 130.96-168.11
Average Volume (10 days) 5.91M
Average Volume (3 months) 101.56M
Market Cap 244.93B
P/E Ratio 38.06
Shares Outstanding 1.77B
Revenue 55.14B
EPS 3.65
Dividend (Yield %) 4.46911
Beta 0.44
Next Earnings Date Feb 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 6, 2023 146.35 1.78 1.23% 144.57 147.01 144.56
Dec 5, 2023 144.51 0.72 0.50% 143.79 145.03 142.53
Dec 4, 2023 144.06 0.80 0.56% 143.26 145.43 143.22
Dec 1, 2023 143.31 0.99 0.70% 142.32 144.00 141.84
Nov 30, 2023 142.33 4.38 3.18% 137.95 142.63 137.52
Nov 29, 2023 138.44 0.48 0.35% 137.96 139.02 137.59
Nov 28, 2023 137.99 -0.47 -0.34% 138.46 139.57 137.81
Nov 27, 2023 139.00 0.54 0.39% 138.46 139.31 137.54
Nov 24, 2023 138.63 -0.73 -0.52% 139.36 139.88 138.39
Nov 22, 2023 138.31 -0.51 -0.37% 138.82 139.69 137.96
Nov 21, 2023 138.66 0.20 0.14% 138.46 139.30 137.68
Nov 20, 2023 138.29 1.32 0.96% 136.97 138.60 136.96
Nov 17, 2023 138.21 0.25 0.18% 137.96 138.79 137.07
Nov 16, 2023 138.22 0.71 0.52% 137.51 138.75 136.98
Nov 15, 2023 137.48 -0.47 -0.34% 137.95 138.07 135.96
Nov 14, 2023 138.00 -0.60 -0.43% 138.60 140.03 137.77
Nov 13, 2023 138.57 0.02 0.01% 138.55 139.08 137.17
Nov 10, 2023 138.55 0.40 0.29% 138.15 139.24 136.35
Nov 9, 2023 137.97 -2.82 -2.00% 140.79 140.85 135.79
Nov 8, 2023 141.94 -1.23 -0.86% 143.17 143.60 141.85

Abbvie Events

Time (UTC) Country Event
Friday, January 12, 2024

Time (UTC)

12:00

Country

US

Event

Abbvie Inc
Abbvie Inc

Forecast

-

Previous

-
Monday, January 15, 2024

Time (UTC)

12:00

Country

US

Event

Abbvie Inc
Abbvie Inc

Forecast

-

Previous

-

Time (UTC)

12:00

Country

US

Event

Abbvie Inc
Abbvie Inc

Forecast

-

Previous

-
Wednesday, February 7, 2024

Time (UTC)

14:30

Country

US

Event

Q4 2023 Abbvie Inc Earnings Release
Q4 2023 Abbvie Inc Earnings Release

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Abbvie Inc Earnings Release
Q1 2024 Abbvie Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 58054 56197 45804 33266 32753
Revenue 58054 56197 45804 33266 32753
Cost of Revenue, Total 16527 17314 15257 7606 7557
Gross Profit 41527 38883 30547 25660 25196
Total Operating Expense 39937 38273 34441 20283 26370
Selling/General/Admin. Expenses, Total 14861 11996 11299 6942 7399
Research & Development 6487 6982 6181 5407 5229
Interest Expense (Income) - Net Operating -167 161
Unusual Expense (Income) 2006 1549 1704 505 5524
Other Operating Expenses, Total 56 432 0 -10 500
Operating Income 18117 17924 11363 12983 6383
Interest Income (Expense), Net Non-Operating -2192 -2435 -2351 -1551 -1168
Other, Net -2448 -2500 -5614 -3006 -18
Net Income Before Taxes 13477 12989 3398 8426 5197
Net Income After Taxes 11845 11549 4622 7882 5773
Net Income Before Extra. Items 11836 11542 4616 7882 5773
Net Income 11836 11542 4616 7882 5687
Total Adjustments to Net Income -54 -74 -60 -40 -30
Income Available to Common Excl. Extra. Items 11782 11468 4556 7842 5743
Income Available to Common Incl. Extra. Items 11782 11468 4556 7842 5657
Diluted Net Income 11782 11468 4556 7842 5657
Diluted Weighted Average Shares 1778 1777 1673 1484 1546
Diluted EPS Excluding Extraordinary Items 6.62655 6.45357 2.72325 5.28437 3.71475
Dividends per Share - Common Stock Primary Issue 5.64 5.2 4.72 4.28 3.59
Diluted Normalized EPS 7.78476 7.31817 3.65923 5.75749 6.27662
Total Extraordinary Items -86
Minority Interest -9 -7 -6
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 13927 13865 12225 15121 14812
Revenue 13927 13865 12225 15121 14812
Cost of Revenue, Total 6467 4208 3972 4134 4228
Gross Profit 7460 9657 8253 10987 10584
Total Operating Expense 11646 9352 9457 9619 10209
Selling/General/Admin. Expenses, Total 3332 3217 2995 3252 3216
Research & Development 1721 1732 1662 1781 1610
Unusual Expense (Income) 126 364 838 453 926
Other Operating Expenses, Total 0 -169 -10 -1 229
Operating Income 2281 4513 2768 5502 4603
Interest Income (Expense), Net Non-Operating -423 -491 -489 -516 -533
Other, Net 95 -1412 -1804 -2021 330
Net Income Before Taxes 1953 2610 475 2965 4400
Net Income After Taxes 1781 2027 241 2472 3952
Minority Interest -3 -3 -2 1 -3
Net Income Before Extra. Items 1778 2024 239 2473 3949
Net Income 1778 2024 239 2473 3949
Total Adjustments to Net Income -11 -11 -11 -18
Income Available to Common Excl. Extra. Items 1778 2013 228 2462 3931
Income Available to Common Incl. Extra. Items 1778 2013 228 2462 3931
Diluted Net Income 1778 2013 228 2462 3931
Diluted Weighted Average Shares 1771 1771 1776 1781 1776
Diluted EPS Excluding Extraordinary Items 1.00395 1.13665 0.12838 1.38237 2.2134
Dividends per Share - Common Stock Primary Issue 1.48 1.48 1.48 1.41 1.41
Diluted Normalized EPS 1.07212 1.33948 0.4171 1.66299 2.70929
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 28463 27928 24173 49519 16945
Cash and Short Term Investments 9229 9830 8479 39924 8061
Cash & Equivalents 9201 9746 8449 39924 7289
Short Term Investments 28 84 30 0 772
Total Receivables, Net 11254 9977 8822 5428 5384
Accounts Receivable - Trade, Net 11254 9977 8822 5428 5384
Total Inventory 3579 3128 3310 1813 1605
Prepaid Expenses 4401 4993 3562 2332 1763
Other Current Assets, Total 22 132
Total Assets 138805 146529 150565 89115 59352
Property/Plant/Equipment, Total - Net 5672 5872 6143 3306 2883
Property/Plant/Equipment, Total - Gross 11723 11489 11754 8532 8396
Accumulated Depreciation, Total -6051 -5617 -5611 -5226 -5513
Goodwill, Net 32156 32379 33124 15604 15663
Intangibles, Net 67439 75951 82876 18649 21233
Long Term Investments 241 277 293 93 1420
Other Long Term Assets, Total 4834 4122 3956 1944 1208
Total Current Liabilities 29538 35194 28661 15585 17239
Accounts Payable 2934 2882 2276 1452 1546
Payable/Accrued 6065 7057 6516 3128 4026
Accrued Expenses 12254 10217 9032 5423 4726
Notes Payable/Short Term Debt 1 14 34 0 3699
Current Port. of LT Debt/Capital Leases 4135 12481 8468 3753 1609
Other Current Liabilities, Total 4149 2543 2335 1829 1633
Total Liabilities 121551 131121 137489 97287 67798
Total Long Term Debt 59135 64189 77554 62975 35002
Long Term Debt 59118 64164 77533 62955 35002
Deferred Income Tax 2190 3009 3646 1130 1067
Other Liabilities, Total 30655 28701 27607 17597 14490
Total Equity 17254 15408 13076 -8172 -8446
Common Stock 18 18 18 18 18
Additional Paid-In Capital 19245 18305 17384 15193 14756
Retained Earnings (Accumulated Deficit) 4784 3127 1055 4717 3368
Treasury Stock - Common -4594 -3143 -2264 -24504 -24108
Unrealized Gain (Loss) 0 0 -10
Other Equity, Total -2199 -2899 -3117 -3596 -2470
Total Liabilities & Shareholders’ Equity 138805 146529 150565 89115 59352
Total Common Shares Outstanding 1769.18 1768.34 1765.13 1478.91 1478.82
Capital Lease Obligations 17 25 21 20
Minority Interest 33 28 21
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 33224 28852 26488 28463 30364
Cash and Short Term Investments 13290 8766 6722 9229 11879
Cash & Equivalents 13287 8759 6711 9201 11832
Short Term Investments 3 7 11 28 47
Total Receivables, Net 11412 11491 11473 11254 10743
Accounts Receivable - Trade, Net 11412 11491 11473 11254 10743
Total Inventory 3981 4055 3833 3579 3172
Prepaid Expenses 4541 4540 4460 4401 4570
Total Assets 136221 135367 134544 138805 141325
Property/Plant/Equipment, Total - Net 4934 4943 4931 4935 4893
Property/Plant/Equipment, Total - Gross 11374 11318 11142 10986 10679
Accumulated Depreciation, Total -6440 -6375 -6211 -6051 -5786
Goodwill, Net 32091 32224 32220 32156 31726
Intangibles, Net 58603 62862 64848 67439 68725
Long Term Investments 275 288 257 241 235
Other Long Term Assets, Total 7094 6198 5800 5571 5382
Total Current Liabilities 34773 32239 27590 29538 32712
Payable/Accrued 29658 27036 24789 25402 23505
Notes Payable/Short Term Debt 2 0 1 1 10
Current Port. of LT Debt/Capital Leases 5113 5203 2800 4135 9197
Total Liabilities 124127 122501 121270 121551 125331
Total Long Term Debt 55631 55812 59292 59135 60399
Long Term Debt 55631 55812 59292 59135 60399
Deferred Income Tax 2044 2124 2110 2190 1972
Minority Interest 35 32 29 33 33
Other Liabilities, Total 31644 32294 32249 30655 30215
Total Equity 12094 12866 13274 17254 15994
Common Stock 18 18 18 18 18
Additional Paid-In Capital 20021 19839 19619 19245 19056
Retained Earnings (Accumulated Deficit) 933 1789 2393 4784 4953
Treasury Stock - Common -6525 -6528 -6524 -4594 -4590
Other Equity, Total -2353 -2252 -2232 -2199 -3443
Total Liabilities & Shareholders’ Equity 136221 135367 134544 138805 141325
Total Common Shares Outstanding 1765.49 1764.8 1763.97 1769.18 1768.4
Capital Lease Obligations
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 11845 11549 4622 7882 5687
Cash From Operating Activities 24943 22777 17588 13324 13427
Cash From Operating Activities 778 803 666 464 471
Amortization 7689 7718 5805 1553 1294
Non-Cash Items 6820 4927 8714 4754 7101
Cash Taxes Paid 2988 3648 1674 1447 35
Cash Interest Paid 2546 2712 2619 1794 1215
Changes in Working Capital -258 -1322 106 -1329 -1126
Cash From Investing Activities -623 -2344 -37557 596 -1006
Capital Expenditures -695 -787 -798 -552 -638
Other Investing Cash Flow Items, Total 72 -1557 -36759 1148 -368
Cash From Financing Activities -24803 -19039 -11501 18708 -14396
Financing Cash Flow Items -1102 -674 -333 -552 -104
Total Cash Dividends Paid -10043 -9261 -7716 -6366 -5580
Issuance (Retirement) of Stock, Net -1225 -690 -769 -621 -11941
Issuance (Retirement) of Debt, Net -12433 -8414 -2683 26247 3229
Foreign Exchange Effects -62 -97 -5 7 -39
Net Change in Cash -545 1297 -31475 32635 -2014
Deferred Taxes -1931 -898 -2325
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 241 11845 9373 5421 4493
Cash From Operating Activities 4193 24943 17515 9913 4908
Cash From Operating Activities 179 778 582 401 198
Amortization 1948 7689 5728 3704 1855
Deferred Taxes -267 -1931 -1415 -794 -194
Non-Cash Items 2917 6820 4348 3620 -169
Changes in Working Capital -825 -258 -1101 -2439 -1275
Cash From Investing Activities -499 -623 -175 -1461 -1591
Capital Expenditures -175 -695 -482 -305 -162
Other Investing Cash Flow Items, Total -324 72 307 -1156 -1429
Cash From Financing Activities -6192 -24803 -15169 -9651 -6972
Financing Cash Flow Items -290 -1102 -776 -456 -225
Total Cash Dividends Paid -2661 -10043 -7537 -5033 -2526
Issuance (Retirement) of Stock, Net -1890 -1225 -1274 -1281 -1342
Foreign Exchange Effects 8 -62 -85 -26 7
Net Change in Cash -2490 -545 2086 -1225 -3648
Issuance (Retirement) of Debt, Net -1351 -12433 -5582 -2881 -2879
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.9811 158520932 -1102065 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.1935 91667533 717450 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.4295 78182567 1156130 2023-06-30 LOW
Capital International Investors Investment Advisor 2.4448 43152741 404379 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 2.2158 39109666 -1259978 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9803 34952938 907917 2023-06-30 LOW
Capital Research Global Investors Investment Advisor 1.8439 32545522 -3168845 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 1.2916 22797052 1260396 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0634 18769556 1466171 2022-12-31 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 1.0131 17881789 -33713 2023-06-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 0.7532 13294516 -686858 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7155 12628445 -487918 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7154 12627584 741031 2023-06-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.687 12125043 319918 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.614 10837075 139722 2023-06-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.6075 10723261 -2772215 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.6039 10658843 -4389662 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.6019 10624630 -1866636 2023-06-30 LOW
UBS Financial Services, Inc. Investment Advisor 0.5741 10133661 244001 2023-06-30 LOW
BofA Global Research (US) Research Firm 0.5574 9838032 -2536190 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AbbVie Company profile

AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually. 

 

Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.

 

The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
 

The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers. 

 

Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion. 


Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.

 

Industry: Pharmaceuticals (NEC)

1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

69.93 Price
-3.200% 1D Chg, %
Long position overnight fee -0.0207%
Short position overnight fee -0.0013%
Overnight fee time 22:00 (UTC)
Spread 0.040

XRP/USD

0.64 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,027.11 Price
+0.510% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.50

BTC/USD

43,984.60 Price
+0.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading